3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
358
Carcinoma, Non-Small-Cell Lung
178
Neoplasms
109
Breast Neoplasms
97
Lung Neoplasms
81
Urinary Bladder Neoplasms
79
Neoplasm Metastasis
74
Ovarian Neoplasms
53
Cholangiocarcinoma
39
Sarcoma
38
Lymphoma
38
Biliary Tract Neoplasms
35
Gallbladder Neoplasms
34
Hodgkin Disease
30
Lymphoma, Non-Hodgkin
27
Adenocarcinoma
27
Lymphoma, Large B-Cell, Diffuse
25
Colorectal Neoplasms
24
Bile Duct Neoplasms
23
Triple Negative Breast Neoplasms
22
Recurrence
22
Fallopian Tube Neoplasms
22
Unspecified Adult Solid Tumor, Protocol Specific
21
Carcinoma, Transitional Cell
21
Carcinoma, Ovarian Epithelial
21
Urethral Neoplasms
20
Carcinoma
17
Adenocarcinoma of Lung
15
Head and Neck Neoplasms
14
Carcinoma, Renal Cell
14
Interventions
Vinorelbine
1
Genz-644282
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metatropic dwarfism
×
Gemcitabine
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts